Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC to Cut Jobs as Part of Restructuring


Thursday, 21 Mar 2013 03:02am EDT 

AstraZeneca PLC announced a restructuring of its SG&A activities that will result in a global reduction in headcount of approximately 2,300. The majority of this headcount impact is related to programs under way or already communicated to affected employees. The Company is combining this SG&A restructuring with two previously announced programs. These comprise the headcount reduction of 1,600 related to the proposed Research & Development footprint changes announced on March 18, 2013, and the balance of the Phase 3 restructuring program announced in February 2012, which amounts to 1,150 roles. The total combined Phase 4 program entails an estimated global headcount reduction of approximately 5,050 over the period between 2013 and 2016. 

Company Quote

72.09
0.4 +0.56%
22 Dec 2014